APA (7th ed.) Citation

Fournier, C., Mercey-Ressejac, M., Derangère, V., Kadi, A. A., Rageot, D., Charrat, C., . . . Marche, P. N. Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour modelResearch in context. Elsevier.

Chicago Style (17th ed.) Citation

Fournier, Carole, et al. Nanostructured Lipid Carriers Based MRNA Vaccine Leads to a T cell–inflamed Tumour Microenvironment Favourable for Improving PD-1/PD-L1 Blocking Therapy and Long-term Immunity in a Cold Tumour ModelResearch in Context. Elsevier.

MLA (9th ed.) Citation

Fournier, Carole, et al. Nanostructured Lipid Carriers Based MRNA Vaccine Leads to a T cell–inflamed Tumour Microenvironment Favourable for Improving PD-1/PD-L1 Blocking Therapy and Long-term Immunity in a Cold Tumour ModelResearch in Context. Elsevier.